Denali Therapeutics Inc.

NasdaqGS:DNLI Stok Raporu

Piyasa değeri: US$3.5b

Denali Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Denali Therapeutics kazanç ve gelirin sırasıyla yıllık 25.6% ve 63.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -36.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

25.6%

Kazanç büyüme oranı

27.4%

EPS büyüme oranı

Biotechs kazanç büyümesi28.3%
Gelir büyüme oranı63.7%
Gelecekteki özkaynak getirisi-36.9%
Analist kapsamı

Good

Son güncelleme26 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:DNLI - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026233-414-107-20611
12/31/202570-486-505-27413
12/31/202412-453-557-35614
9/30/2024N/A-427-376-363N/A
6/30/20241-420-402-391N/A
3/31/2024295-137-425-413N/A
12/31/2023331-145-371-358N/A
9/30/2023341-124-348-332N/A
6/30/2023343-128-321-302N/A
3/31/2023101-371-248-231N/A
12/31/2022108-326-263-245N/A
9/30/2022111-303-254-238N/A
6/30/2022112-284-234-222N/A
3/31/202283-286-243-233N/A
12/31/202149-291-220-211N/A
9/30/202135330361368N/A
6/30/202135756404410N/A
3/31/202134058415420N/A
12/31/202033671413416N/A
9/30/202024-228-150-145N/A
6/30/202028-216-183-176N/A
3/31/202026-215-193-176N/A
12/31/201927-198-169-152N/A
9/30/2019148-66-27-11N/A
6/30/2019135-55-30-15N/A
3/31/2019133-52-19-14N/A
12/31/2018129-364750N/A
9/30/20183-137-64-61N/A
6/30/20182-123N/A-49N/A
3/31/20181-91N/A-24N/A
12/31/2017N/A-88N/A-77N/A
9/30/2017N/A-85N/A-77N/A
6/30/2017N/A-93N/A-76N/A
3/31/2017N/A-90N/A-75N/A
12/31/2016N/A-87N/A-72N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: DNLI şirketinin gelirinin (yıllık 63.7% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: DNLI şirketinin gelirinin (yıllık 63.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DNLI 3 yıl içinde kârsız olması bekleniyor.


Büyüyen şirketleri keşfedin